Advice
References
References
Burger RA, Brady MF, Bookman MA et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. The New England Journal of Medicine 365: 2473–83
Cancer Research UK (2012) Ovarian cancer risks and causes [online; accessed 19 July 2013]
Cocks K, King MT, Velikova G et al. (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer quality of life questionnaire core 30. Journal of Clinical Oncology 29: 89–96
European Medicines Agency (2013) Avastin [online; accessed 19 July 2013]
MIMS (2013) Avastin (POM) [online; accessed 19 July 2013]
National Institute for Health and Care Excellence (2013) Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. NICE technology appraisal guidance 285
National Institute for Health and Care Excellence (2013) Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer. NICE technology appraisal guidance 284
National Institute for Health and Clinical Excellence (2012) Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer. NICE technology appraisal guidance 263
National Institute for Health and Clinical Excellence (2012) Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal 150 and part review of technology appraisal guidance 118). NICE technology appraisal guidance 242
National Institute for Health and Clinical Excellence (2011) Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer. NICE technology appraisal guidance 214
National Institute for Health and Clinical Excellence (2010) Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer. NICE technology appraisal guidance 212
National Institute for Health and Clinical Excellence (2007) Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. NICE technology appraisal guidance 118
National Institute for Health and Clinical Excellence (2011) Ovarian cancer: the recognition and initial management of ovarian cancer. NICE clinical guideline 122
NHS England (2013) Cancer drugs fund list [online; accessed 19 July 2013]
Perceptive Informatics (2013) RECIST [online; accessed 19 July 2013]
Perren TJ, Swart AM, Pfisterer J et al. (2011) A phase 3 trial of bevacizumab in ovarian cancer. The New England Journal of Medicine 365: 2484–96
Roche Products Limited (2013) Avastin 25mg/ml concentrate for solution for infusion summary of product characteristics [online; accessed 19 July 2013]
Roche Products Limited (2013) Direct healthcare professional communication on cases of necrotising fasciitis reported with Avastin [online; accessed 19 July 2013]
Stark D, Nankivell M, Pujade-Lauraine E et al. (2013) Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The Lancet Oncology 14: 236–43